Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20589069 | 0.90 | EPHX2 (0.43) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20588187 | 0.87 | EPHX2 (0.43) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20588802 | 0.81 | SMN1; SMN2 (0.47) | EPHX2SMN1; SMN2NPC1RAB9APDK1 | |
| SCHEMBL23502339 | 0.80 | CYP17A1 (0.45) | SMN1; SMN2L3MBTL1PDK1PDK2PDK3 | |
| SCHEMBL20588181 | 0.80 | EPHX2 (0.37) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21840421 | 0.78 | DHODH (0.43) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28459398 | 0.75 | EPHX2 (0.52) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2096237 | 0.75 | EPHX2 (0.52) | EPHX2KIF11SMN1; SMN2NPC1RAB9A | |
| SCHEMBL935645 | 0.75 | EPHX2 (0.73) | EPHX2KIF11NPC1RAB9APTGS1 | |
| SCHEMBL3434346 | 0.74 | SMN1; SMN2 (0.71) | EPHX2SMN1; SMN2NPC1RAB9AMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380533-A1 | 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS | ASTRAZENECA AB (SE) | 2021-12-09 | — | — | US | disclosed |
| US-11034654-B2 | 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators | ASTRAZENECA AB (SE) | 2021-06-15 | — | — | US | disclosed |
| EP-3638661-A1 | 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-20200115338-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2020-04-16 | — | — | US | disclosed |
| WO-2018229155-A1 | 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS | ASTRAZENECA AB (SE) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115338-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | EPHX2 1977/4885KIF11 2594/4885SMN1; SMN2 1617/4885 |
| US-11034654-B2 | 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators | RORA, RORC, RORB | EPHX2 2047/4885KIF11 3040/4885SMN1; SMN2 2438/4885 |
| US-20210380533-A1 | 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS | RORA, RORC, RORB | EPHX2 2047/4885KIF11 3040/4885SMN1; SMN2 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.